CareDx, Inc., is a publicly held commercial stage company that develops, markets and delivers a diagnostics surveillance solution for heart transplant recipients to help clinicians make personalized treatment decisions throughout a patient’s lifetime. Its commercialized testing solution, the AlloMap heart transplant molecular test, or AlloMap, is a blood-based tool used to monitor heart transplant recipients for acute cellular rejection. CareDx is seeking to apply its expertise in heart transplantation towards the development of additional solutions for organ transplant recipients, including recipients of heart and kidney transplants.
CareDx trades on the NASDAQ exchange under the ticker symbol “CDNA”.
CareDx completed its initial public offering on July 16, 2014.
The Company’s headquarters is located in Brisbane, California, in the San Francisco Bay Area. Principal offices are located at 3260 Bayshore Blvd, Brisbane CA 94005. The telephone number is (415) 287-2300.
The biographies of CareDx’s directors are available in the “Board of Directors” section of our Investor Relations website.
The biographies of CareDx’s directors are available in the “Management” section of our Investor Relations website.
CareDx’s fiscal year ends December 31st.
CareDx’s independent auditor is Ernst & Young LLP, with its address at 275 Shoreline Drive, Suite 600, Redwood City, CA 94065. The phone number is (650) 802-4500.
CareDx’s outside legal counsel is Paul Hastings.
No, CareDx does not pay a dividend at this time.
No, CareDx does not offer a direct stock purchase program.
CareDx’s quarterly and annual reports and other SEC filings are available by selecting the “Financial Information” section of our “Investors” page on our website or through SEC’s website.
The next annual stockholders meeting for 2017 will be on July 13.
CareDx uses Computershare as its transfer agent and contact information is provided below.
P.O. Box 30170
College Station, TX 77842-3170
Toll Free: 1 (877) 272-9616
Outside U.S.: 1 (201) 680-6578
Please see our “Events & Presentations” section of our website for a listing of upcoming earnings announcements and other key events.
You can contact CareDx’s Investor Relations via email by clicking here.
CareDx, Inc. was incorporated in the state of Delaware on December 21, 1998.
The IPO was underwritten and managed by Piper Jaffray & Co, Leerink Partners LLC, Raymond James and Mizuho Securities.
If your shares are held in street name (by your broker), you must notify the securities firm holding your stock. If you hold stock certificates in your name, address changes should be submitted in writing by U.S. Mail to our transfer agent:
P.O. Box 30170
College Station, TX 77842
You can contact CareDx’s Media Relations via email by clicking here.
Please submit your question using the form below.